Sellas Life Sciences
SLS
11.31
-0.03
-0.26%
Sellas Life Sciences
US · SLS
#2687 by market cap
Listed 1970
11.31
-0.03
-0.26%
Live - 5344 symbols - heartbeat 267s ago
· 2026-10-08 07:39
Pre-market
11.27
-0.35%
After-hours
11.35
+0.35%
Overnight
11.32
+0.09%
- Market cap
- 2.28B
- P/E (TTM)i
- -51.41
- P/Bi
- 16.58
- EPSi
- -0.25
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SLS?
Anonymous reader poll. Unscientific, not investment advice.
About Sellas Life Sciences
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
- Founded
- 2006
- CEO
- Dr. Angelos M. Stergiou, M.D.,Sc.D.
- Employees
- 13
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- sellaslifesciences.com
Company profile
- Exchange
- US
- Symbol
- SLS
- Market-cap rank
- #2687
- Listing date
- 1970-01-01
- Market cap
- 2.28B
- Float cap
- 2.27B
- Shares out
- 201.95M
- Float shares
- 201.15M
Sectors & themes
Quote time 2026-10-08 07:39:48 · For reference only, not investment advice and not tailored to your situation.